Lercanidipin Accord

Lercanidipine, the active ingredient in Lercanidipin Accord, is a calcium channel blocker presented as an oral tablet for oral administration. It works by relaxing vascular smooth muscle, thereby reducing peripheral vascular resistance and lowering elevated blood pressure in adult patients diagnosed with hypertension.

GNH USA supplies Lercanidipin Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring product quality through stringent manufacturing standards and regulatory adherence. The company provides reliable logistics and documentation support for global distribution.

Lercanidipine is used as an antihypertensive agent acting on the calcium‑channel pathway to control high blood pressure.

- Hypertension: reduces systolic and diastolic blood pressure, helping patients reach target levels in primary hypertension. - Isolated systolic hypertension: improves arterial compliance and lowers pressure in elderly patients with elevated systolic readings.

Lercanidipine may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity. - Flushing: transient warmth and redness of the skin. - Peripheral edema: swelling of the ankles or lower legs. - Dizziness: especially upon standing. - Tachycardia: increased heart rate. - Fatigue: general feeling of tiredness.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure requiring medical attention. - Myocardial infarction: rare occurrence of heart attack. - Hepatic injury: signs of liver dysfunction. - Allergic reaction: rash, itching, or swelling. - Arrhythmia: abnormal heart rhythm.

Before initiating therapy, consider the following safety measures.

- Blood pressure monitoring: regularly assess to ensure therapeutic response. - Cardiac assessment: evaluate for existing heart disease before use. - Concomitant antihypertensives: adjust doses to avoid excessive hypotension. - Hepatic impairment: use with caution in patients with liver dysfunction. - Abrupt discontinuation: taper dose to prevent rebound hypertension. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lercanidipine can interact with several medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma levels. - Other calcium channel blockers: additive vasodilatory effect can cause hypotension. - Grapefruit juice: can elevate drug concentration.

Moderate Interactions (Monitor Closely):\n- Diuretics: may enhance blood pressure‑lowering effect. - Beta‑blockers: combined effect may require dose adjustment. - ACE inhibitors or ARBs: monitor for excessive blood pressure reduction.